<div><div></div><div><span><p><span>Cumberland Pharmaceuticals reported first-quarter 2026 results showing revenue of $9.13M and a net loss attributable to common shareholders of $3.29M, or diluted EPS of ($0.22), compared with revenue of $11.71M and net income of $1.26M, or EPS $0.08, in the year-ago quarter.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current quarter</span></td><td><span>Prior year quarter</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>$9.13M</span></td><td><span>$11.71M</span></td><td><span>(22%)</span></td></tr><tr><td><span>Net income²</span></td><td><span>($3.29M)</span></td><td><span>$1.26M</span></td><td><span>(361.7%)</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>($0.22)</span></td><td><span>$0.08</span></td><td><span>(375%)</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Net revenues”. ² Reported as “Net income (loss) attributable to common shareholders”. ³ Reported as “Income (loss) per share attributable to common shareholders”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Total net revenues fell to $9.1M from $11.7M, driven primarily by the loss of a $3.0M 2025 milestone and lower Kristalose shipments.</span></li><li><span>Sancuso and Vibativ showed volume growth; Talicia launched U.S. promotion activity and contributed $1.9M in Q1 2026.</span></li><li><span>Ifetroban advanced in development, receiving FDA Fast Track designation for Duchenne muscular dystrophy and continuing Phase II trials in systemic sclerosis and idiopathic pulmonary fibrosis; the company plans to retain development programs post-transaction.</span></li><li><span>Cumberland agreed to sell its U.S. branded portfolio to Apotex for $100M and will provide transition services while refocusing on its pipeline and clinical development efforts.</span></li></ul><p><span>Original SEC Filing: </span>CUMBERLAND PHARMACEUTICALS INC [ CPIX ] - 10-Q - May. 08, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

CPIX

LABU

<p>Cumberland Pharmaceuticals reported Q1 2026 revenue of $9.13M, down 22% from $11.71M in the prior year, with a net loss of $3.29M and diluted EPS of ($0.22). The decline was attributed to the loss of a $3.0M milestone and reduced Kristalose shipments. However, Sancuso and Vibativ saw volume growth, and Talicia contributed $1.9M. The company plans to sell its U.S. branded portfolio to Apotex for $100M while focusing on its pipeline and clinical development efforts.</p>

TradingView

Cumberland Pharma

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VanEck Biotech ETF

iShares Biotechnology ETF

VG Health

iShares US Pharma

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Cumberland Pharmaceuticals 1Q 2026: Revenue $9.13M, EPS ($0.22) — 10-Q Summary